<DOC>
	<DOCNO>NCT02442700</DOCNO>
	<brief_summary>Dyslipidemia risk factor cardiovascular disease ( CVD ) increase problem HIV-infected patient antiretroviral therapy especially protease inhibitor include atazanavir . Pitavastatin new HMG-CoA reductase inhibitor less drug-drug interaction demonstrable efficacy decrease lipid level non HIV-infected individual . The study conduct randomize , double-blind , crossover study compare safety efficacy pitavastatin versus placebo HIV-infected patient dyslipidemia receive atazanavir/ritonavir . Patients randomize receive either placebo pitavastatin 12 week , underwent 2-week washout period , give treatment additional 12 week . Patients observe lipid profile include total cholesterol ( TC ) , triglyceride ( TG ) , low density lipoprotein ( LDL ) high density lipoprotein ( HDL ) ; side effect include clinical laboratory ( serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) creatinine phosphokinase ( CPK ) ) . The follow-up visit every 4 week end study .</brief_summary>
	<brief_title>Effects Pitavastatin Lipid Profiles HIV-infected Patients With Dyslipidemia Receiving Atazanavir/Ritonavir</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>age ≥18 year able provide inform consent confirm HIV infection ART include atazanavir 300 mg ritonavir 100 mg day regimens change within 12 week randomization patient cholesterol level 200 500 LDL 130 400 mg/dL without lipidlowering agent discontinue lipidlowering agent least 1 month prior randomization history pitavastatin and/or constituent drug allergy know history myocardial infarction and/or ischemic stroke within 1 month prior randomization would endanger stop previous lipidlowering agent enrollment abnormal AST ALT level ≥5 time asymptomatic patient ≥3 time upper normal limit ( UNL ) symptomatic patient pregnancy breastfeed cyclosporine major drug interaction pitavastatin patient deny join study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV-infected patient dyslipidemia receive atazanavir/ritonavir</keyword>
</DOC>